Member Info for Fruitsnveg

"Clearly Polygon knew not one single thing more than we did when they took their huge punt on Synairgen".

Hedge funds don't make punts. They make very calculated investments. The above statement is laughable.

and the proof?

If you have proof of Polygon losing "100s of millions on Feb 21st" please do post it here Doc.Daneeka. I'd be delighted to understand how they have lost "100s of millions" ?

No one could have predicted P3 results, but they would have had a sound understanding of the probability/likelihood and would have had mitigations in place. it is inconceivable to me that they suffered the same losses as us PIs in Feb 2022. There are many financial instruments available to them., many investment strategies. Buying shares is but one. Griffiths is a smart cookie. I agree with you, I tend to think how they have behaved in the past is fairly indicative of how they will behave in the future, but none of us know for certain so it is always very wise to DYOR.

"They like the same stuff we've liked recently, but they haven't got a single clue about what will happen with the pandemic or whether govts will continue supporting trials or what else will be coming down the track to treat hospitalised patients." . They are a hedge-fund with some incredibly smart and well-researched people guiding their investment decisions. Of course they know what is likely to happen based on available data, and of course they know what Government funding and spending plans are. they are well connected , switched on and ruthless. They know.

'Buy up' was a poor choice of words on my part, 'invest in' is what I meant. Interesting.

Sounds like Reade wants to buy up the whole supply chain... Nebuliser -> mail order -> patient ?

"We no longer have an active commercialisation roadmap". Actually we do, it's just in 'sleep mode'. Our BOD had the foresight to kick off a series of pre-commercialisation activities that will see us hit the ground running when the time is right, don't worry. Then again, we may not need to do so much heavy commercial lifting, if a JV or licencing deal or 3 come to fruition?

It's always interesting to read what the experts think about what to expect ref Covid. They seem to know so much more than us punters, but then I suppose that is why they are the experts:

"Concerns about a possible new surge arise from a combination of three factors: human behavior, the evolution of the virus and overall waning immunity protection from vaccines and prior infection, said UCSF infectious disease expert Peter-Chin Hong. And a recent rise in cases and hospitalizations in Europe, which has often been a COVID bellwether for the U.S., is heightening the unease.

“The question is not whether we will see an increase in cases and hospitalizations — we will — but by how much,” Chin-Hong wrote in an email.

What could happen next
For the late fall and winter season, Chin-Hong outlined two possible scenarios. One is a “modest increase” of cases due to a large proportion of the population already infected this year, combined with vaccines and boosters, resulting in “a highly protected community.”

The updated vaccine booster, which is formulated to fight the original omicron strain and BA.4 and BA.5, could give the U.S. an advantage over Europe, which is using a booster that fights the original strain and BA.1, he said.

The second scenario is a “larger surge of cases and hospitalizations” because not enough people have received the updated boosters.

Last week, the Centers for Disease Control and Prevention updated its definition of what it means to be “up to date” on vaccination to be the primary vaccine series plus the updated booster. But the latest CDC data shows that only about 4% of the eligible population has gotten the new shot.

That raises the potential that “emerging variants like BF.7 that are more immune evasive may fuel more infections, which will lead to a round of disruptions in society once again: school and work absences, missed Thanksgiving dinners, short-staffed restaurants and canceled Broadway shows,” Chin-Hong said."

https://www.sfchronicle.com/health/article/COVID-variants-surge-17487479.php

And another: https://endpts.com/astrazeneca-nabs-a-small-rare-disease-gene-therapy-player-for-667-premium/

It was more the "Additional biobucks could bring the deal’s total value north of $400 million" that registered my interest.
For that I would get out of bed.

Poly will be happy, I'd imagine.

Nice one

https://endpts.com/sanofi-licenses-a-preclinical-genetic-disease-drug-from-an-unknown-biotech-spun-out-of-the-nih/

Not too shoddy for a small unheard of pre-clinical Biotech. It shows BP is willing to make bets just like the rest of us.

They may choose an ISS instead of a PT because it's quicker and will, ultimately, realise more shareholder value. This cannot be ruled out.

"Synairgen continues to actively pursue and refine multiple clinical approaches including company- and investigator-sponsored studies and possibly platform studies (as and when appropriate), to confirm the most expeditious clinical development path for SNG001 in patients hospitalised "

"possibly", not definitely.

"as and when appropriate", not guaranteed.

As the RNS states, the company will NOT necessarily choose a Platform Trial if they can achieve a more "expeditious clinical development path for SNG001 in patients hospitalised" via an ISS (investigator-sponsored study) or a company-sponsored one. Read it carefully.

"Synairgen continues to actively pursue and refine multiple clinical approaches including company- and investigator-sponsored studies and possibly platform studies (as and when appopriate), to confirm the most expeditious clinical development path for SNG001 in patients hospitalised "

This clearly intentional use of the conditional idiom "as and when appropriate", in relation to PT trials - do we think this indicates that a PT trial, is slipping down the priority list? Given this intentional wording, I do. Could it be that the long-awaited A2 news will be a catalyst in 'discussions' that one would assume have likely been ongoing? Would you absolutely need a PT when the signals just keep adding up? Maybe a PT trial is now just a cherry on the cake, very nice to have, but not essential to the visual and/or taste experience. We've had some icing applied today which should act as a sufficient sweetner, without a PT cherry plonked on top as well? As always, just my thoughts, DYOR. This is making me so hungry ......

Subtle?

I said "widened". Not changed. Not pivoted. Widened. More respiratory viruses resulting in more hospitalizations widens the net for SNG001 to prove efficiency as a broad-spectrum antiviral. As RM said yesterday, some of those viruses coming through the hospital door will be Covid. Some, but NOT all. We should not be limiting ourselves to just Covid when there are many other viruses to test it's broad-spectrum antiviral efficacy this Winter.

Our remit has widened Doc. Daneeka. The myriad of respiratory viruses that were banished for 3 years by masks and hand washing are now returning at pace to wreak havoc with lungs.. Covid is no longer the sole pathogen at the party. The company have placed themselves at the heart of a larger fight, and for investors, that is a very good thing. Covid, still here, along with many more we can target too.